

Mikko Aimo Oskari Heikinheimo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6544903/publications.pdf>

Version: 2024-02-01

143
papers

3,719
citations

126708
33
h-index

168136
53
g-index

147
all docs

147
docs citations

147
times ranked

2880
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of 2SC, AKR1B10, and FH Antibodies as Potential Biomarkers for FH-deficient Uterine Leiomyomas. <i>American Journal of Surgical Pathology</i> , 2022, 46, 537-546.	2.1	8
2	Reproductive changes among women in their 40s: A cross-sectional study. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2022, 101, 248-255.	1.3	4
3	Good News About Endometriosis and Preterm Delivery. <i>JAMA Network Open</i> , 2022, 5, e2147794.	2.8	0
4	ESHRE guideline: endometriosis. <i>Human Reproduction Open</i> , 2022, 2022, hoac009.	2.3	379
5	Associations between use of psychotropic medications and use of hormonal contraception among girls and women aged 15-49 years in Finland: a nationwide, register-based, matched case-control study. <i>BMJ Open</i> , 2022, 12, e053837.	0.8	3
6	Estradiol Valerate vs Ethinylestradiol in Combined Oral Contraceptives: Effects on the Pituitary-Ovarian Axis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3008-e3017.	1.8	6
7	Histopathologic and Molecular Characterization of Uterine Leiomyoma-like Inflammatory Myofibroblastic Tumor. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1126-1136.	2.1	8
8	Systemic hormonal contraception and risk of venous thromboembolism. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2022, 101, 846-855.	1.3	13
9	Use of reproductive health services among women using long- or short-acting contraceptive methods - a register-based cohort study from Finland. <i>BMC Public Health</i> , 2022, 22, .	1.2	1
10	Surgically confirmed endometriosis in adolescents in Finland - A register-based cross-sectional cohort study. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2022, 101, 1065-1073.	1.3	6
11	Norethisterone and its acetate - what's so special about them?. <i>BMJ Sexual and Reproductive Health</i> , 2021, 47, 102-109.	0.9	17
12	Pregnancy and delivery outcomes in women with rectovaginal endometriosis treated either conservatively or operatively. <i>Fertility and Sterility</i> , 2021, 115, 406-415.	0.5	5
13	Ethinyl estradiol vs estradiol valerate in combined oral contraceptives - Effect on glucose tolerance: A randomized, controlled clinical trial. <i>Contraception</i> , 2021, 103, 53-59.	0.8	12
14	Contraception After an Induced Abortion and Childbirth. <i>Trends in Andrology and Sexual Medicine</i> , 2021, , 229-242.	0.1	0
15	A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of Ursodeoxycholic acid with Rifampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC randomised trial. <i>BMC Pregnancy and Childbirth</i> , 2021, 21, 51.	0.9	21
16	Fear of childbirth after medical vs surgical abortion. Population-based register study from Finland. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2021, 100, 743-750.	1.3	6
17	More than just contraception: the impact of the levonorgestrel-releasing intrauterine system on public health over 30 years. <i>BMJ Sexual and Reproductive Health</i> , 2021, 47, 228-230.	0.9	3
18	Thirty years of mirena: A story of innovation and change in women's healthcare. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2021, 100, 614-618.	1.3	14

#	ARTICLE	IF	CITATIONS
19	Municipal contraceptive services, socioeconomic status and teenage pregnancy in Finland: a longitudinal study. <i>BMJ Open</i> , 2021, 11, e043092.	0.8	2
20	Population-level indicators associated with hormonal contraception use: a register-based matched caseâ€“control study. <i>BMC Public Health</i> , 2021, 21, 465.	1.2	1
21	Celebrating 100Âyears of <i>AOGS</i> with a focus on global health. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2021, 100, 561-563.	1.3	0
22	Use of universally offered family planning services â€“ a cohort study in the city of Vantaa, Helsinki metropolitan area, Finland. <i>Scandinavian Journal of Public Health</i> , 2021, , 140349482110027.	1.2	1
23	Incidence of extraovarian clear cell cancers in women with surgically diagnosed endometriosis: A cohort study. <i>PLoS ONE</i> , 2021, 16, e0253270.	1.1	0
24	Deficient H2A.Z deposition is associated with genesis of uterine leiomyoma. <i>Nature</i> , 2021, 596, 398-403.	13.7	53
25	Parity associates with chromosomal damage in uterine leiomyomas. <i>Nature Communications</i> , 2021, 12, 5448.	5.8	2
26	Contraceptive priorities among women seeking family planning services in Finland in 2017â€“2019. <i>Contraception</i> , 2021, 104, 394-400.	0.8	1
27	The Risk of Psychiatric Morbidity Following Teenage Induced Abortion and Childbirthâ€“A Longitudinal Study From Finland. <i>Journal of Adolescent Health</i> , 2020, 66, 345-351.	1.2	5
28	Associations between hormonal contraception use, sociodemographic factors and mental health: a nationwide, register-based, matched caseâ€“control study. <i>BMJ Open</i> , 2020, 10, e040072.	0.8	8
29	Predictors of choosing long-acting reversible contraceptive methods when provided free-of-charge â€“ A prospective cohort study in Finland. <i>Contraception</i> , 2020, 101, 370-375.	0.8	8
30	Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 886.e1-886.e17.	0.7	14
31	Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 252, 7-14.	0.5	14
32	Early provision of intrauterine contraception as part of abortion careâ€“5-year results of a randomised controlled trial. <i>Human Reproduction</i> , 2020, 35, 796-804.	0.4	10
33	Estradiol Valerate in COC Has More Favorable Inflammatory Profile Than Synthetic Ethinyl Estradiol: A Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2483-e2490.	1.8	13
34	Pain during medical abortion in early pregnancy in teenage and adult women. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2020, 99, 1603-1610.	1.3	9
35	Mortality of midlife women with surgically verified endometriosisâ€“a cohort study including 2.5 million person-years of observation. <i>Human Reproduction</i> , 2019, 34, 1576-1586.	0.4	6
36	Induced abortion and future use of IVF treatment; A nationwide register study. <i>PLoS ONE</i> , 2019, 14, e0225162.	1.1	6

#	ARTICLE	IF	CITATIONS
37	Contraception: satisfaction with the method, effects on sleep and psychological well-being. <i>BMJ Sexual and Reproductive Health</i> , 2019, 45, 169.1-171.	0.9	1
38	Contraception after pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019, 98, 1378-1385.	1.3	15
39	A cohort study of 49 933 women with surgically verified endometriosis: Increased incidence of breast cancer below the age of 40. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019, 98, 1113-1119.	1.3	8
40	Long-Acting Reversible Contraception Free of Charge, Method Initiation, and Abortion Rates in Finland. <i>American Journal of Public Health</i> , 2018, 108, 538-543.	1.5	23
41	Cervical biomarkers as predictors of successful induction of labour by Foley catheter. <i>Journal of Obstetrics and Gynaecology</i> , 2018, 38, 927-932.	0.4	8
42	Authors' reply re: Immediate versus delayed initiation of the levonorgestrel-releasing intrauterine system following medical termination of pregnancy – 1-year continuation rates: a randomised controlled trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 93-93.	1.1	0
43	Risk factors and the choice of long-acting reversible contraception following medical abortion: effect on subsequent induced abortion and unwanted pregnancy. <i>European Journal of Contraception and Reproductive Health Care</i> , 2018, 23, 89-96.	0.6	10
44	Circulating pathogen-specific plasmablasts in female patients with upper genital tract infection. <i>Journal of Reproductive Immunology</i> , 2018, 126, 69-75.	0.8	0
45	Trends in the incidence rate, type and treatment of surgically verified endometriosis – a nationwide cohort study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2018, 97, 59-67.	1.3	27
46	Cancer risk of <i>Lichen planus</i>: A cohort study of 13,100 women in Finland. <i>International Journal of Cancer</i> , 2018, 142, 18-22.	2.3	59
47	Induced Abortion in a Population Entitled to Free-of-Charge Long-Acting Reversible Contraception. <i>Obstetrics and Gynecology</i> , 2018, 132, 1453-1460.	1.2	13
48	Predicting poor compliance with follow-up and intrauterine contraception services after medical termination of pregnancy. <i>BMJ Sexual and Reproductive Health</i> , 2018, 44, 278-285.	0.9	8
49	Ecological study on the use of hormonal contraception, abortions and births among teenagers in the Nordic countries. <i>BMJ Open</i> , 2018, 8, e022473.	0.8	11
50	A Nationwide Cohort Study on the risk of non-gynecological cancers in women with surgically verified endometriosis. <i>International Journal of Cancer</i> , 2018, 143, 2725-2731.	2.3	20
51	Criminalised abortion in UK obstructs reflective choice and best care. <i>BMJ: British Medical Journal</i> , 2018, 362, k2928.	2.4	2
52	Risk of Gynecologic Cancer According to the Type of Endometriosis. <i>Obstetrics and Gynecology</i> , 2018, 131, 1095-1102.	1.2	76
53	Sexual well-being after first trimester termination of pregnancy: Secondary analysis of a randomized contraceptive trial. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2018, 97, 1447-1454.	1.3	2
54	Most women living with HIV can deliver vaginally – National data from Finland 1993 – 2013. <i>PLoS ONE</i> , 2018, 13, e0194370.	1.1	12

#	ARTICLE	IF	CITATIONS
55	Genetic predisposition to uterine leiomyoma is determined by loci for genitourinary development and genome stability. <i>ELife</i> , 2018, 7, .	2.8	58
56	The current status of hormonal therapies for heavy menstrual bleeding. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 40, 111-120.	1.4	15
57	Induced abortion and mental health. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2017, 96, 383-383.	1.3	2
58	Lichen sclerosus and risk of cancer. <i>International Journal of Cancer</i> , 2017, 140, 1998-2002.	2.3	91
59	In Reply. <i>Obstetrics and Gynecology</i> , 2017, 129, 944-945.	1.2	0
60	Interpregnancy Interval After Termination of Pregnancy and the Risks of Adverse Outcomes in Subsequent Birth. <i>Obstetrics and Gynecology</i> , 2017, 129, 347-354.	1.2	15
61	Intrauterine contraception after medical abortion: factors affecting success of early insertion. <i>Contraception</i> , 2017, 95, 257-262.	0.8	13
62	Increased risk of premature death following teenage abortion and childbirthâ€”a longitudinal cohort study. <i>European Journal of Public Health</i> , 2017, 27, 845-849.	0.1	9
63	Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids. <i>Contemporary Clinical Trials</i> , 2017, 55, 56-62.	0.8	28
64	Contraceptive use in the Nordic countries. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2017, 96, 19-28.	1.3	80
65	Global metabolomic profiling of uterine leiomyomas. <i>British Journal of Cancer</i> , 2017, 117, 1855-1864.	2.9	29
66	Declining prevalence of cytological squamous intraepithelial lesions of the cervix among women living with wellâ€”controlled <scp>HIV</scp> â€” Most women living with <scp>HIV</scp> do not need annual <scp>PAP</scp> smear screening. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2017, 96, 1330-1337.	1.3	8
67	Real-world research and the role of observational data in the field of gynaecology â€” a practical review. <i>European Journal of Contraception and Reproductive Health Care</i> , 2017, 22, 250-259.	0.6	18
68	High birth rates despite easy access to contraception and abortion: a crossâ€”sectional study. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2017, 96, 1414-1422.	1.3	12
69	Fast-track vs. delayed insertion of the levonorgestrel-releasing intrauterine system after early medical abortion â€” a randomized trial. <i>Contraception</i> , 2017, 96, 344-351.	0.8	10
70	The dishonourable disobedience of not providing abortion. <i>European Journal of Contraception and Reproductive Health Care</i> , 2017, 22, 81-81.	0.6	1
71	In reply to the Letter to the Editor. <i>European Journal of Public Health</i> , 2017, 27, 794-795.	0.1	0
72	Medical treatment of second-trimester fetal miscarriage; A retrospective analysis. <i>PLoS ONE</i> , 2017, 12, e0182198.	1.1	6

#	ARTICLE	IF	CITATIONS
73	Determinants of underage induced abortion – the 1987 Finnish Birth Cohort study. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2016, 95, 572-579.	1.3	7
74	Foley Catheter or Oral Misoprostol for Induction of Labor in Women with Term Premature Rupture of Membranes: A Randomized Multicenter Trial. <i>American Journal of Perinatology</i> , 2016, 33, 866-872.	0.6	29
75	Deep infiltrating endometriosis affecting the urinary tract – surgical treatment and fertility outcomes in 2004 – 2013. <i>Gynecological Surgery</i> , 2016, 13, 435-444.	0.9	25
76	Anxiety and quality of life after first-trimester termination of pregnancy: a prospective study. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2016, 95, 1171-1180.	1.3	11
77	Is underage abortion associated with adverse outcomes in early adulthood? A longitudinal birth cohort study up to 25 years of age. <i>Human Reproduction</i> , 2016, 31, 2142-2149.	0.4	23
78	Warm welcome to NFOG2016!. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2016, 95, 9-9.	1.3	0
79	Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1315-1320.	3.3	166
80	Yes we can! Successful examples of disallowing “conscientious objection” in reproductive health care. <i>European Journal of Contraception and Reproductive Health Care</i> , 2016, 21, 201-206.	0.6	33
81	Management of Foley catheter induction among nulliparous women: a retrospective study. <i>BMC Pregnancy and Childbirth</i> , 2015, 15, 276.	0.9	6
82	Use of hormonal therapy is associated with reduced nerve fiber density in deep infiltrating, rectovaginal endometriosis. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2015, 94, 693-700.	1.3	26
83	Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception. <i>Human Reproduction</i> , 2015, 30, 1580-1588.	0.4	29
84	Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial. <i>Lancet, The</i> , 2015, 385, 698-704.	6.3	66
85	Complications and long-term follow-up on colorectal resections in the treatment of deep infiltrating endometriosis extending to bowel wall. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2015, 94, 72-79.	1.3	43
86	Medical Management of Heavy Menstrual Bleeding. <i>Obstetrical and Gynecological Survey</i> , 2015, 70, 115-130.	0.2	46
87	Management of prolonged pregnancy by induction with a Foley catheter. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2015, 94, 608-614.	1.3	8
88	Provision of intrauterine contraception in association with first trimester induced abortion reduces the need of repeat abortion: first-year results of a randomized controlled trial. <i>Human Reproduction</i> , 2015, 30, 2539-2546.	0.4	29
89	Predicting Painful or Difficult Intrauterine Device Insertion in Nulligravid Women. <i>Obstetrics and Gynecology</i> , 2014, 124, 345-353.	1.2	43
90	Medical termination of pregnancy during the second versus the first trimester and its effects on subsequent pregnancy. <i>Contraception</i> , 2014, 89, 109-115.	0.8	6

#	ARTICLE	IF	CITATIONS
91	Is teenage pregnancy an obstetric risk in a welfare society? A population-based study in Finland, from 2006 to 2011. <i>BMJ Open</i> , 2013, 3, e003225.	0.8	109
92	Uterine perforation caused by intrauterine devices: clinical course and treatment. <i>Human Reproduction</i> , 2013, 28, 1546-1551.	0.4	66
93	Safety and efficacy of the levonorgestrel-releasing intrauterine system: recent insights. <i>Expert Review of Obstetrics and Gynecology</i> , 2013, 8, 235-247.	0.4	6
94	Intrauterine contraception: incidence and factors associated with uterine perforation—a population-based study. <i>Human Reproduction</i> , 2012, 27, 2658-2663.	0.4	58
95	Risk factors of surgical evacuation following second-trimester medical termination of pregnancy. <i>Contraception</i> , 2012, 86, 141-146.	0.8	9
96	Further evidence for lack of negative associations between hormonal contraception and mental health. <i>Contraception</i> , 2012, 86, 470-480.	0.8	46
97	Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS). <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2012, 91, 3-9.	1.3	33
98	Comparison of rates of adverse events in adolescent and adult women undergoing medical abortion: population register based study. <i>BMJ: British Medical Journal</i> , 2011, 342, d2111-d2111.	2.4	31
99	Attendance at post-abortal follow-up visits is low - can the risks of non-attendance be identified?. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2011, 90, 543-546.	1.3	10
100	Recent developments in the clinical use of the levonorgestrel-releasing intrauterine system. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2011, 90, 1177-1188.	1.3	18
101	The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 126.e1-126.e4.	0.7	37
102	One- and two-day dosing intervals between mifepristone and misoprostol in second trimester medical termination of pregnancy—a randomized trial. <i>Human Reproduction</i> , 2011, 26, 2690-2697.	0.4	35
103	Medical abortion in lactating women — low levels of mifepristone in breast milk. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010, 89, 618-622.	1.3	22
104	Young age and termination of pregnancy during the second trimester are risk factors for repeat second-trimester abortion. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 107.e1-107.e7.	0.7	20
105	Radical excision of rectovaginal endometriosis results in high rate of pain relief — results of a long-term follow-up study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010, 89, 71-77.	1.3	17
106	Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system. <i>Contraception</i> , 2010, 81, 481-486.	0.8	50
107	New clinical data on consecutive use of the levonorgestrel-releasing intrauterine system. <i>Expert Review of Obstetrics and Gynecology</i> , 2010, 5, 275-277.	0.4	0
108	Immediate Complications After Medical Compared With Surgical Termination of Pregnancy. <i>Obstetrics and Gynecology</i> , 2009, 114, 795-804.	1.2	71

#	ARTICLE	IF	CITATIONS
109	Rectovaginal Endometriosisâ€“Characteristics of Operative Treatment and Factors Predicting Bowel Resection. <i>Journal of Minimally Invasive Gynecology</i> , 2009, 16, 302-306.	0.3	20
110	Frequency and Risk Factors for Repeat Abortions After Surgical Compared With Medical Termination of Pregnancy. <i>Obstetrics and Gynecology</i> , 2009, 113, 845-852.	1.2	31
111	Age, parity, history of abortion and contraceptive choices affect the risk of repeat abortion. <i>Contraception</i> , 2008, 78, 149-154.	0.8	162
112	Contraception and HIV infection in women. <i>Human Reproduction Update</i> , 2008, 15, 165-176.	5.2	39
113	Can the outcome of the next pregnancy be predicted at the time of induced abortion?. <i>Human Reproduction</i> , 2008, 24, 820-826.	0.4	23
114	Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study. <i>Human Reproduction</i> , 2007, 22, 2515-2522.	0.4	27
115	Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women. <i>Contraception</i> , 2007, 75, 37-39.	0.8	33
116	Termination of early pregnancy using flexible, low-dose mifepristoneâ€“misoprostol regimens. <i>Contraception</i> , 2007, 76, 456-460.	0.8	15
117	Misoprostol-only versus mifepristone plus misoprostol in induction of labor following intrauterine fetal death. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2007, 86, 701-705.	1.3	21
118	Long-cycle combined contraception: less bleeding and increased subject satisfaction. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2006, 85, 517-518.	1.3	3
119	The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected womenâ€“effects on bleeding patterns, ovarian function and genital shedding of HIV. <i>Human Reproduction</i> , 2006, 21, 2857-2861.	0.4	55
120	Prevalence and risk factors of squamous intraepithelial lesions of the cervix among HIV-infected women â€“ a long-term follow-up study in a low-prevalence population. <i>International Journal of STD and AIDS</i> , 2006, 17, 831-834.	0.5	14
121	Effect of antiprogesterone mifepristone followed by misoprostol on circulating leptin in early pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2005, 84, 134-139.	1.3	3
122	Pregnancy outcome among HIV-infected women in the Helsinki metropolitan area. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2005, 84, 945-950.	1.3	6
123	Late follicular phase administration of mifepristone suppresses circulating leptin and FSH â€“ mechanism(s) of action in emergency contraception?. <i>European Journal of Endocrinology</i> , 2005, 152, 411-418.	1.9	8
124	Mifepristone may inhibit the midcycle gonadotropin surge at both ovarian and pituitary sites of action. <i>Fertility and Sterility</i> , 2005, 84, 1545-1546.	0.5	1
125	Pregnancy outcome among HIV-infected women in the Helsinki metropolitan area. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2005, 84, 945-950.	1.3	2
126	Advanced cervical pregnancy: uterus-sparing therapy initiated with a combination of methotrexate and mifepristone followed by evacuation and local hemostatic measures. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2004, 83, 211-212.	1.3	9

#	ARTICLE	IF	CITATIONS
127	One- and 2-day mifepristoneâ€“misoprostol intervals are both effective in medical termination of second-trimester pregnancy. <i>Reproductive BioMedicine Online</i> , 2004, 8, 236-239.	1.1	37
128	Advanced cervical pregnancy: uterus-sparing therapy initiated with a combination of methotrexate and mifepristone followed by evacuation and local hemostatic measures. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2004, 83, 211-212.	1.3	7
129	The learning curve is rapid in medical termination of pregnancyâ€”first-year results from the Helsinki area. <i>Contraception</i> , 2003, 67, 223-227.	0.8	20
130	The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogesterin action. <i>Contraception</i> , 2003, 68, 421-426.	0.8	72
131	Pharmacokinetics of 10 mg of mifepristone. <i>Contraception</i> , 2003, 68, 427-429.	0.8	12
132	Termination of Pregnancy with Mifepristone and Prostaglandin Suppresses Transiently Circulating Glucocorticoid Bioactivity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 323-326.	1.8	17
133	The kinetics of serum hCG and progesterone in response to oral and vaginal administration of misoprostol during medical termination of early pregnancy. <i>Human Reproduction</i> , 2002, 17, 2315-2319.	0.4	36
134	Clinical Pharmacokinetics of Mifepristone. <i>Clinical Pharmacokinetics</i> , 1997, 33, 7-17.	1.6	76
135	Alterations in the pituitary-thyroid and pituitary-adrenal axesâ€”consequences of long-term mifepristone treatment. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 292-296.	1.5	43
136	Endometrial effects of RU486 in primatesâ€”Antiproliferative action despite signs of estrogen action and increased cyclin-B expression. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1996, 59, 179-190.	1.2	32
137	Pharmacokinetics of mifepristone after low oral doses. <i>Contraception</i> , 1996, 54, 229-234.	0.8	35
138	Pharmacokinetics of the antiprogesterone RU 486: No correlation to clinical performance of RU 486. <i>European Journal of Endocrinology</i> , 1990, 123, 298-304.	1.9	22
139	Distribution of RU 486 and Its Demethylated Metabolites in Humans*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989, 68, 270-275.	1.8	54
140	Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration. <i>The Journal of Steroid Biochemistry</i> , 1989, 32, 21-25.	1.3	44
141	Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486. <i>Fertility and Sterility</i> , 1988, 49, 961-963.	0.5	92
142	Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography. <i>Contraception</i> , 1986, 34, 613-624.	0.8	65
143	Contraception after abortion. , 0, , 114-121.		0